Treatment of advanced soft tissue sarcomas with a modified CYVADIC protocol

M. Raphael Pfeffer; Aaron Sulkes; Shoshana Biran

doi:10.1159/000225845

Treatment of advanced soft tissue sarcomas with a modified CYVADIC protocol

M. Raphael Pfeffer^*, Aaron Sulkes, Shoshana Biran

^*Corresponding author for this work

Hadassah University Medical Centre

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

33 consecutive patients with metastatic or locally recurrent soft tissue sarcoma were treated with a modification of the CYVADIC (cyclophosphamide, vincristine. Adriamycin. dacarbazine) protocol. In an attempt to enhance the response rate without increasing the toxicity, the dose of Adriamycin was raised to 60 mg/m² and the dose of cyclophosphamide to 600 mg/m2 in each cycle. The dose of dacarbazine was decreased to 150 mg/m²/day for 5 days. Of 31 evaluable patients there were 4 complete responses (13%) and 9 partial responses for a total response rate of 39%. 11 patients (33%) had minimal response or stable disease. The response achieved with our dose modification was no better than that achieved in several series with conventionally dosed CYVADIC.

Original language	English
Pages (from-to)	308-313
Number of pages	6
Journal	Oncology
Volume	41
Issue number	5
DOIs	https://doi.org/10.1159/000225845
State	Published - 1984
Externally published	Yes

Keywords

Adriamycin dose
Advanced disease
CYVADIC
Chemotherapy
Sarcomas
Soft tissue

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000225845

Cite this

@article{9b18e98b04f34a0b9f92963de8ba3f30,

title = "Treatment of advanced soft tissue sarcomas with a modified CYVADIC protocol",

abstract = "33 consecutive patients with metastatic or locally recurrent soft tissue sarcoma were treated with a modification of the CYVADIC (cyclophosphamide, vincristine. Adriamycin. dacarbazine) protocol. In an attempt to enhance the response rate without increasing the toxicity, the dose of Adriamycin was raised to 60 mg/m2 and the dose of cyclophosphamide to 600 mg/m2 in each cycle. The dose of dacarbazine was decreased to 150 mg/m2/day for 5 days. Of 31 evaluable patients there were 4 complete responses (13%) and 9 partial responses for a total response rate of 39%. 11 patients (33%) had minimal response or stable disease. The response achieved with our dose modification was no better than that achieved in several series with conventionally dosed CYVADIC.",

keywords = "Adriamycin dose, Advanced disease, CYVADIC, Chemotherapy, Sarcomas, Soft tissue",

author = "Pfeffer, {M. Raphael} and Aaron Sulkes and Shoshana Biran",

year = "1984",

doi = "10.1159/000225845",

language = "אנגלית",

volume = "41",

pages = "308--313",

journal = "Oncology",

issn = "0030-2414",

publisher = "S. Karger AG",

number = "5",

}

TY - JOUR

T1 - Treatment of advanced soft tissue sarcomas with a modified CYVADIC protocol

AU - Pfeffer, M. Raphael

AU - Sulkes, Aaron

AU - Biran, Shoshana

PY - 1984

Y1 - 1984

N2 - 33 consecutive patients with metastatic or locally recurrent soft tissue sarcoma were treated with a modification of the CYVADIC (cyclophosphamide, vincristine. Adriamycin. dacarbazine) protocol. In an attempt to enhance the response rate without increasing the toxicity, the dose of Adriamycin was raised to 60 mg/m2 and the dose of cyclophosphamide to 600 mg/m2 in each cycle. The dose of dacarbazine was decreased to 150 mg/m2/day for 5 days. Of 31 evaluable patients there were 4 complete responses (13%) and 9 partial responses for a total response rate of 39%. 11 patients (33%) had minimal response or stable disease. The response achieved with our dose modification was no better than that achieved in several series with conventionally dosed CYVADIC.

AB - 33 consecutive patients with metastatic or locally recurrent soft tissue sarcoma were treated with a modification of the CYVADIC (cyclophosphamide, vincristine. Adriamycin. dacarbazine) protocol. In an attempt to enhance the response rate without increasing the toxicity, the dose of Adriamycin was raised to 60 mg/m2 and the dose of cyclophosphamide to 600 mg/m2 in each cycle. The dose of dacarbazine was decreased to 150 mg/m2/day for 5 days. Of 31 evaluable patients there were 4 complete responses (13%) and 9 partial responses for a total response rate of 39%. 11 patients (33%) had minimal response or stable disease. The response achieved with our dose modification was no better than that achieved in several series with conventionally dosed CYVADIC.

KW - Adriamycin dose

KW - Advanced disease

KW - CYVADIC

KW - Chemotherapy

KW - Sarcomas

KW - Soft tissue

UR - http://www.scopus.com/inward/record.url?scp=0021172970&partnerID=8YFLogxK

U2 - 10.1159/000225845

DO - 10.1159/000225845

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:0021172970

SN - 0030-2414

VL - 41

SP - 308

EP - 313

JO - Oncology

JF - Oncology

IS - 5

ER -

Treatment of advanced soft tissue sarcomas with a modified CYVADIC protocol

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this